CRYSVITA (burosumab-twza)

OFFICE ADMINISTRATION

Indications for Prior Authorization:

  • Treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older

Patients must meet the following criteria for the indication(s) above:

  • Patient is 1 year of age or older, AND
  • Diagnosis of X-linked hypophosphatemia (XLH), AND
  • Prescribed by or in consultation with an endocrinologist or nephrologist, AND
  • Patient has a baseline serum phosphorus level below normal range for age, AND
  • Patient has a baseline tubular reabsorption of phosphate corrected for glomerular filtration rate that was below the normal range for age and gender, AND
  • Patient will not use oral phosphate and active Vitamin D analogs, AND
  • Patient does not have severe renal impairment or end stage renal disease

Dosing:

  • Pediatric XLH:
    • Starting dose: 0.8 mg/kg of body weight rounded to the nearest 10 mg, administered every 2 weeks. Minimum dose 10 mg up to a maximum dose of 90 mg.
    • Do not adjust Crysvita more frequently than every 4 weeks.
    • Dose may be increased up to approximately 2 mg/kg (maximum 90 mg), administered every 2 weeks to achieve normal serum phosphorus
  • Adult XLH:
    • Dose regimen: 1 mg/kg body weight rounded to the nearest 10 mg up to a maximum dose of 90 mg administered every 4 weeks

Approval:

  • 1 year

Last review date: April 30, 2019

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone